

Advancing the Acceptance and Use of the Human Thyroid Microtissue Assay

Chad Deisenroth, Ph.D.

Center for Computational Toxicology and Exposure

U.S. EPA

deisenroth.chad@epa.gov

ICCVAM Public Forum July 22, 2025

Disclaimer: The views expressed are those of the author and do not necessarily reflect the views or policies of the U.S. Environmental Protection Agency.





Availability of NAMs in the Endocrine Disruptor Screening Program

Availability of New Approach Methodologies (NAMs) in the Endocrine Disruptor Screening Program (EDSP)

December 13, 2022




EPA's Office of Chemical Safety and Pollution Prevention Office of Pesticide Programs in collaboration with Office of Research and Development

- The EDSP evaluates chemical effects on estrogen, androgen, and thyroid endocrine pathways.
- The validated Estrogen Receptor (ER) and Androgen Receptor (AR)
 pathway models may be used as an alternative to the Tier 1 screening
 assays.
- Additional NAMs including Integration of Bioactivity Exposure Ratios (IBER), QSAR models for ER and AR activity, and SeqAPASS for cross-species extrapolation may be used as Other Scientifically Relevant Information (OSRI) to prioritize chemicals for screening and hazard assessment.
- Continue development of a Thyroid Pathway Framework that includes in vitro assays for thyroid-relevant targets to produce an integrated prediction model that may be used as OSRI for thyroid system perturbations.




Thyroid 'MIE' Assays Do Not Directly Measure the 'Key Event' for Thyroid Hormone Synthesis

Sites of Interference for Thyroid Disrupting Chemicals



Thyroid AOP Network




| Thyroid MIE | Assay | Environmental Chemicals Screened | Active Chemicals | % Active | Reference |
|-------------|----------------------|----------------------------------|------------------|----------|--|
| TSHR | Engineered Cell Line | 7871 | 825 | 10 | TCPL: TOX21_TSHR_Agonist, TOX21_TSHR_Antagonist |
| TPO | Microsomal Enzyme | 1074 | 150 | 14 | K. Paul Friedman et al, ToxSci, 151(1), 2016, 160-180 |
| NIS | Engineered Cell Line | 293 | 137 | 47 | J. Wang et al, EnvironSciTechn, 52, 2018, 5417-5426 |
| NIS | Engineered Cell Line | 768 | 167 | 22 | J. Wang et al, Environment International, 126, 2019, 377-386 |
| DIO 1 | Recombinant Enzyme | 292 | 18 | 6 | M. Hornung et al, ToxSci, 162(2), 2018, 570–581 |
| DIO 1 | Recombinant Enzyme | 1819 | 139 | 8 | J. Olker et al, ToxSci, 168(2), 2019, 430-442 |
| IYD | Recombinant Enzyme | 1825 | 148 | 8 | J. Olker et al, Toxicol In Vitro. 2021 Mar;71:105073. |

DOI: 10.1210/endocr/bqaa106; DOI: 10.1289/EHP5297



Human Thyroid Microtissue Assay



Goal: Establish a validated test method for human thyroid hormone disruption.



Filling Technology Gaps for In Vitro Thyroid Testing



TOXICOLOGICAL SCIENCES, 174(1), 2020, 63–78
doi: 10.1093/noxsci/kfz/238
Advance Access Fublication Date: December 6, 2019
Research Article




APPLIED IN VITRO TOXICOLOGY Volume XX, Number XX, 2021 © Mary Ann Liebert, Inc. DOI: 10.1089/aivt.2020.0027




Development of an *In Vitro* Human Thyroid Microtissue Model for Chemical Screening


Chad Deisenroth , *1 Valerie Y. Soldatow, † Jermaine Ford, † Wendy Stewart, * Cassandra Brinkman, * Edward L. LeCluyse, † Denise K. MacMillan, † and Russell S. Thomas *



Characterization of Novel Human Immortalized Thyroid Follicular Epithelial Cell Lines

Kristen Hopperstad,^{1,*} Theresa Truschel,^{2,*} Tom Wahlicht,² Wendy Stewart,¹ Andrew Eicher,¹ Tobias May,² and Chad Deisenroth^{1,†}






- A thyroid AOP 'key event' assay designed to evaluate disruption of thyroid hormone synthesis as a mode-of-action for endocrine-related hazard screening.
- Established commercial sources of primary human thyrocytes and immortalized cell lines which enhances method accessibility.



Increasing Confidence in the Human Thyroid Microtissue Assay as a New Approach Method







Fig 2: Framework for developing robust NAMs.

https://doi.org/10.22427/NICEATM-2



Technical Characterization: Standardizing Organotypic Assays is Challenging

"I want an assay that is reproducible"



"I want an assay that predicts a range of human responses"

Goal: Minimize technical variability to increase confidence in the 'true' biological performance.



Standardization of the Human Thyroid Microtissue Assay



Toxicological Sciences, 2024, 1-19

https://doi.org/10.1093/toxsci/kfae014 Advance Access Publication Date: February 4, 2024 Research article


Technical evaluation and standardization of the human thyroid microtissue assay


Briana Foley, ¹ Kristen Hopperstad, ¹ John Gamble, ^{1,2} Scott G. Lynn, ³ Russell S. Thomas D, ¹ Chad Deisenroth


- Defined optimal donor procurement specifications.
- Established qualification criteria for primary human thyrocytes.
- Established minimum assay performance guidelines.
- Set benchmark ranges for reference chemical responses.

Donor Cohort Demographic Summary


| Donors | 32 |
|--------|--------------------------------------|
| Age | 34 (17-61) |
| Sex | Male (24), Female (8) |
| Race | Caucasian (25), African American (7) |
| BMI | 28 (18-37) |







Goodness of Fit



- - Population EC₁₀ (95% CI)



Inter-laboratory Validation of the Human Thyroid Microtissue Assay

Goal: To assess the test method reliability and reproducibility.




Objectives

- SOP refinement.
- 2. Test method training, transfer and intra-laboratory model performance evaluation.
- 3. Limited inter-laboratory reference chemical testing and assay performance evaluation.



Experimental Plan






Donor Selection


| Lab | Study Phase | Donor ID | Age | Sex | Race | ВМІ | Vials per Lab | Experimental Replicates per Lab |
|---------|-------------|------------|-----|-----|------------------|-----|---------------|---------------------------------|
| 1,2,3,4 | 2,3 | EPATHY0035 | 22 | F | Caucasian | 24 | 8 | 3-5 |
| 1,2 | 4 | EPATHY0015 | 40 | F | Caucasian | 29 | 6 | 4 |
| 1,3 | 4 | EPATHY0025 | 44 | F | Caucasian | 20 | 6 | 4 |
| 1,4 | 4 | EPATHY0058 | 37 | М | African American | 34 | 6 | 4 |


- Phase 2-3: One qualified donor evaluated across all laboratories.
- Phase 4: Three qualified donors run in the method developer lab (Lab 1) to benchmark results. One matched donor per partner lab for comparison.
- All selected donors met previously reported qualification criteria (https://doi.org/10.1093/toxsci/kfae014).



Phase 2-3: Human Thyroid Microtissue Assay – Method Transfer












Phase 4: Human Thyroid Microtissue Assay – Method Validation










Reference Chemicals

| CASRN | Chemical Name | CoA Purity | Concentration (mM) | Assay Classification | |
|------------|-----------------------|------------|--------------------|-----------------------|--|
| 16752-77-5 | Methomyl | 99.5 | 20.70 | Negative | |
| 60-56-0 | Methimazole | 100 | 20.21 | Positive (Antagonist) | |
| 51-52-5 | 6-Propyl-2-thiouracil | 99.2 | 20.40 | Positive (Antagonist) | |
| 7601-89-0 | Sodium perchlorate | 99.5 | 20.40 | Positive (Antagonist) | |
| 67-68-5 | Dimethyl sulfoxide | 100 | na | Solvent Control | |



- Chemicals were independently procured by NICEATM via MRIGlobal (Kansas City, MO) and shipped to all laboratories with unique chemical codes for each chemical x laboratory pair.
- Blinding of coded chemicals was maintained for the duration of phase 4 until data collection and analysis had been completed for all laboratories.



EPATHY0058 – Microtissue Biomass

Donor EPATHY0058

Race: African American


Sex: Male


Age: 37

BMI: 34


Thyroid Disease: None Reported

Qualified: Yes






- Dynamic range indicated consistent relative responses to TSH stimulation.
- Precision of responses indicated consistent cell seeding.






EPATHY0058 – Assay Performance Metrics






■ Lab 1

Lab 4




T4 - Screening Quality



- T4 concentrations and effect size across control groups were similar between labs.
- Mean precision, dynamic range, and screening quality values met published acceptance criteria for both labs.



EPATHY0058 – Reference Chemicals (T4)



| | EPATHY0058 - T4 AC50 (μM) | | | |
|-----------------------|---------------------------|-------|--|--|
| Chemical | Lab 1 | Lab 4 | | |
| Methomyl | 2.84 | NA | | |
| Methimazole | 0.306 | 0.260 | | |
| 6-Propyl-2-thiouracil | 0.494 | 0.336 | | |
| Sodium Perchlorate | 29 | 22 | | |

- Effect size and potency were generally equivalent across labs.
- True Positive actives: 6/6. True Negative: 1/2.
- False positive was observed for Methomyl in Lab 1 at the highest tested concentration. 17



Data Interpretation Procedure

- 4.1.12: Reference Chemical Evaluation Data Interpretation Procedure
 - Purpose: To classify the T4 bioactivity and cytotoxicity of the test chemicals.

| | Hit Call | | | |
|----|--------------|---|--|--|
| T4 | Cytotoxicity | Test Chemical Classification | | |
| 0 | 0 | Inactive | | |
| 1 | 0 | Active; non-cytotoxic | | |
| 0 | 1 | nactive; cytotoxic | | |
| | | If T4 LOEC < ATP LOEC; flag as active, cytotoxic | | |
| 1 | 1 | If T4 LOEC ≥ ATP LOEC; flag as equivocal, cytotoxic | | |
| | | If T4 LOEC > ATP LOEC; flag as inactive, cytotoxic | | |

• Evaluation was performed on the hit calls made from the thyroid hormone and cytotoxicity measurements, modeling, and analyses across data aggregated from all experiments (N=4).



Bioactivity Classifications

| Lab | Donor | Chemical | T4 | Cytotoxicity | Classification_Expected | Classification_Observed | Concordance | Reproducibility (%) |
|-----|------------|-----------------------|----|--------------|-------------------------|-------------------------|-------------|---------------------|
| 1 | EPATHY0015 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | 70.8 |
| 2 | EPATHY0015 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0025 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 3 | EPATHY0025 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0058 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 4 | EPATHY0058 | 6-Propyl-2-thiouracil | 1 | 1 | Active; non-cytotoxic | Active; cytotoxic** | 0 | |
| 1 | EPATHY0015 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 2 | EPATHY0015 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0025 | Methimazole | 1 | 1 | Active; non-cytotoxic | Active; cytotoxic** | 0 | |
| 3 | EPATHY0025 | Methimazole | 1 | 1 | Active; non-cytotoxic | Active: cytotoxic** | 0 | |
| 1 | EPATHY0058 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 4 | EPATHY0058 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0015 | Methomyl | 0 | 0 | Inactive | Inactive | 1 | |
| 2 | EPATHY0015 | Methomyl | 1 | 0 | Inactive | Active; non-cytotoxic** | 0 | |
| 1 | EPATHY0025 | Methomyl | 0 | 1 | Inactive | Inactive; cytotoxic** | 0 | |
| 3 | EPATHY0025 | Methomyl | 0 | 0 | Inactive | Inactive | 1 | |
| 1 | EPATHY0058 | Methomyl | 1 | 0 | Inactive | Active; non-cytotoxic** | 0 | |
| 4 | EPATHY0058 | Methomyl | 0 | 0 | Inactive | Inactive | 1 | |
| 1 | EPATHY0015 | Sodium perchlorate | 1* | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 2 | EPATHY0015 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0025 | Sodium perchlorate | 1 | 1 | Active; non-cytotoxic | Equivocal: cytotoxic** | 0 | |
| 3 | EPATHY0025 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0058 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 4 | EPATHY0058 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |

^{*} Based on bioactivity that exceeds the upper bound cutoff.

Hit calls: 0= inactive, 1= active Concordance: 0= no, 1= yes

- Sensitivity for T4 bioactivity was 92%.
 - The overall reproducibility of bioactivity classifications (% concordance) was 71%.


^{**} Incorrectly classified.



Application: Screening of TSHR-Prioritized Chemicals in Human Thyrocyte Assays

Orthogonal Screening for Thyroid Stimulating Hormone Receptor Modulators in Human Thyroid Assays

Briana Foley¹, Kristen Breaux¹, Mahmoud Shobair¹, Madison Feshuk¹, Ann M. Richard^{1,2}, Russell S. Thomas¹, Katie Paul Friedman¹, Chad Deisenroth^{1§}



Integration of thyroid microtissues into an AOP-based tiered screening paradigm to support the context of use.

Tox21 TSHR Assay
Hit Prioritization Workflow

Chemical prioritization and selection based on bio activity, structural diversity, assay specificity, and general promiscuity.

Primary Screening for TSHR
Mechanistic Effects

2D Human Thyroglobulin Assay: Confirmation of TSHR bioactivity in normal human thyrocytes using a native protein biomarker.

Secondary Screening for Functional Effects

3D Human Thyroid Microtissue Assay: Extension of mechanistic activity to functional effects on thyroid hormone synthesis in human microtissues.

Enrichment of TSHR Modulators in Human Thyrocytes

Hazard screening results revealed 2 agonist and 13 antagonist chemicals that demonstrated concordant activity across the assay formats.



Acknowledgements



Rusty Thomas Chad Deisenroth

Briana Foley

Kristen Hopperstad



Bayer CropScience Lab 4

Julia Kuehnlenz Helen Tinwell Frederic Schorsch Olivier Blanck



Lab 2

Eda Rogers Ed LeCluyse Jingsong Chen Sharon Presnell Paul Gallant



Bridgett Hill Agnes Karmaus Michaela Blaylock **Emily Reinke** Nicole Kleinstreuer

Helena Hogberg-Durdock

Contact

deisenroth.chad@epa.gov



Lab 3

Wei Chen Jessica LaRocca Enrica Bianchi Mercedes Biven

Validation Management Team (VMT)

Steve Ferguson (NIEHS) Suzanne Fitzpatrick (FDA) Mike Wade (Health Canada) Donna Mendrick (FDA) Andrei Komarov (CPSC) Ingrid Langezaal (EC JRC) Takao Ashikaga (NIHS) Kumiko Ogawa (NIHS)



Thyroid Microtissue References


- Deisenroth C, Soldatow VY, Ford J, Stewart W, Brinkman C, LeCluyse EL, MacMillan DK, Thomas RS. Development of an In Vitro Human Thyroid Microtissue Model for Chemical Screening. Toxicol Sci. 2020 Mar 1;174(1):63-78. doi: 10.1093/toxsci/kfz238. PMID: 31808822; PMCID: PMC8061085.
- Hopperstad K, Truschel T, Wahlicht T, Stewart W, Eicher A, May T, Deisenroth C. Characterization of Novel Human Immortalized Thyroid Follicular Epithelial Cell Lines. Appl In Vitro Toxicol. 2021 Jun 16;7(2):39-49. doi: 10.1089/aivt.2020.0027. PMID: 35663474; PMCID: PMC9157743.
- Foley B, Hopperstad K, Gamble J, Lynn SG, Thomas RS, Deisenroth C. Technical evaluation and standardization of the human thyroid microtissue assay. Toxicol Sci. 2024 Apr 29;199(1):89-107. doi: 10.1093/toxsci/kfae014. PMID: 38310358; PMCID: PMC11784494.
- Foley B, Breaux K, Shobair M, Feshuk M, Richard AM, Thomas RS, Paul Friedman K, Deisenroth C. Orthogonal Screening for Thyroid Stimulating Hormone Receptor Modulators in Human Thyroid Assays. Toxicol Sci. 2025. Accepted for publication.



Supplementary



Phase 2-3: Human Thyroid Microtissue Assay – Method Transfer



- All labs consistently reproduced microtissue formation with high precision.
- 3 of 4 labs reproduced thyroid hormone synthesis that met all acceptance criteria.



ToxCast Pipeline (TCPL) Data Analysis

- The EPA ToxCast program has historically modeled medium- and high-throughput screening data from a heterogenous source of chemicals, assay technologies, and experimental designs. This has yielded concentration-response data of essentially every permutation imaginable, presenting challenges for accurate data modeling and analysis.
- The ToxCast data pipeline (TCPL) was originally developed to format, normalize, model, and analyze these datasets. It is a standard tool for consistent and reproducible curve-fitting that generally works for all types of data.
- The most recent update of TCPL uses 10 different models to maximize the best fitting curves to the empirical data (doi.org/10.3389/ftox.2023.1275980). Continuous hit calls are made to determine if statistically significant effects are observed based on uncertainties in the data modeling and parameters for defining assay-dependent biological effects.
- Thyroid data will be accessible to the public on the EPA CompTox Chemicals Dashboard (https://comptox.epa.gov/dashboard/).



Bioactivity Classifications (TCPL Analysis)

| Lab | Donor | Chemical | T4 | Cytotoxicity | Classification_Expected | Classification_Observed | Concordance | Reproducibility (%) |
|-----|------------|-----------------------|----|--------------|-------------------------|-------------------------|-------------|---------------------|
| 1 | EPATHY0015 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | 91.7 |
| 2 | EPATHY0015 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0025 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 3 | EPATHY0025 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0058 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 4 | EPATHY0058 | 6-Propyl-2-thiouracil | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0015 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 2 | EPATHY0015 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0025 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 3 | EPATHY0025 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0058 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 4 | EPATHY0058 | Methimazole | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0015 | Methomyl | 0 | 0 | Inactive | Inactive | 1 | |
| 2 | EPATHY0015 | Methomyl | 0 | 0 | Inactive | Inactive | 1 | |
| 1 | EPATHY0025 | Methomyl | 0 | 1 | Inactive | Inactive; cytotoxic** | 0 | |
| 3 | EPATHY0025 | Methomyl | 0 | 0 | Inactive | Inactive | 1 | |
| 1 | EPATHY0058 | Methomyl | 0 | 0 | Inactive | Inactive | 1 | |
| 4 | EPATHY0058 | Methomyl | 0 | 0 | Inactive | Inactive | 1 | |
| 1 | EPATHY0015 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 2 | EPATHY0015 | Sodium perchlorate | 0 | 0 | Active; non-cytotoxic | Inactive** | 0 | |
| 1 | EPATHY0025 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 3 | EPATHY0025 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 1 | EPATHY0058 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |
| 4 | EPATHY0058 | Sodium perchlorate | 1 | 0 | Active; non-cytotoxic | Active; non-cytotoxic | 1 | |

^{*} Based on bioactivity that exceeds the upper bound cutoff.

Hit calls: 0= inactive, 1= active Concordance: 1= yes, 0= no

The overall reproducibility of bioactivity classifications (% concordance) was 92%.

^{**} Incorrectly classified.

Sensitivity for T4 bioactivity was 96%.